ArticleScientific reports2025
Associations between asprosin, insulin resistance, and oxidative stress in adults with obesity.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Trial
- Umbilical cord asprosin and subfatin levels in relation to neonatal metabolic outcomes in gestational diabetes mellitus: a cross-sectional study.BMC endocrine disorders · 2026Article
- Elevated asprosin in hypertension: evidence from an exploratory case-control study.Scientific reports · 2026Article
- The triglyceride-glucose index in chronic kidney disease: a narrative review.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The global increase in obesity is strongly associated with insulin resistance (IR) and related metabolic impairments. Asprosin (ASP), a glucogenic adipokine induced by fasting, has recently emerged as a potential biomarker of IR and abnormal body composition. However, its physiological role in obesity remains incompletely understood. To evaluate the associations between serum ASP levels, IR indices, oxidative stress markers (OS), liver function and inflammation parameters, and body composition in overweight and obese adults during a standardized 4-hour oral glucose tolerance test (OGTT). This cross-sectional study included 150 adults categorized by BMI into three groups: control (CG; BMI < 25 kg/m²), overweight (O1; BMI > 25 kg/m²), and obese (O2; BMI > 30 kg/m²). Participants underwent dual-energy X-ray absorptiometry (DXA), including visceral adipose tissue quantification, bioelectrical impedance analysis (BIA), and biochemical assessment. Measurements included serum ASP, C-peptide, HbA1c, lipid profile, total oxidative capacity (TOC), total antioxidative capacity (TAC), liver transaminases (ALT, AST) and C-reactive protein (CRP). IR was assessed using HOMA-IR, QUICKI, Matsuda Index, TyG, and the composite TyG-WHR index as a proxy for hepatic IR. ASP levels were significantly higher in O1 and O2 compared with CG (p < 0.001), and in O2 compared with O1 (p < 0.01). ASP positively correlated with fat mass, TOC, HOMA-IR, TyG, TyG-WHR, ALT, and CRP, and negatively with muscle mass, total body water, resting metabolic rate, QUICKI, and Matsuda Index (p < 0.05). ASP is strongly associated with IR and adverse metabolic profiles in obesity. Its preferential correlation with hepatic IR markers (TyG-WHR, ALT, CRP) and fat mass suggests that ASP may primarily reflect liver-specific metabolic dysfunction rather than peripheral IR. These findings highlight ASP as a promising biomarker and potential therapeutic target in obesity-related metabolic disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.